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In the present study, we report a kindred with hearing loss, congenital heart defects, and posterior embryotoxon,
segregating as autosomal dominant traits. Six of seven available affected patientsmanifestedmild-to-severecombined
hearing loss, predominantly affecting middle frequencies. Two patients were diagnosed with vestibular pathology.
All patients had congenital heart defects, including tetralogy of Fallot, ventricular septal defect, or isolated peripheral
pulmonic stenosis. No individual in this family met diagnostic criteria for any previously described clinical syndrome.
A candidate-gene approach was undertaken and culminated in the identification of a novel Jagged 1 (JAG1) missense
mutation (C234Y) in the first cysteine of the first epidermal-growth-factor–like repeat domain of the protein. JAG1
is a cell-surface ligand in the Notch signaling pathway. Mutations in JAG1 have been identified in patients with
Alagille syndrome. Our findings revealed a unique phenotype with highly penetrant deafness, posterior embryotoxon,
and congenital heart defects but with variable expressivity in a large kindred, which demonstrates that mutation
in JAG1 can cause hearing loss.
Congenital heart disease is the most common birth de-
fect, occurring in ∼1% of live births. Although multi-
factorial inheritance has been postulated for the major-
ity of cases, single-gene transmission is demonstrated
by the observation of mutations in NKX2.5 or Jagged
1 (JAG1 [MIM 601920]; GenBank accession num-
ber XM_056118), within families segregating congenital
heart defects (Schott et al. 1998; Eldadah et al. 2001).
JAG1 encodes a highly conserved ligand within the Notch
family, which consists of components of an intercellular
signaling pathway shown to be crucial for cell-fate de-
cisions in organisms spanning the phylogenetic spectrum
(Lindsell et al. 1996; Lissemore and Starmer 1999). JAG1
Received March 1, 2002; accepted for publication April 15,
2002; electronically published May 17, 2002.
Address for correspondence and reprints: Dr. Ce´dric Le Caignec,
Laboratoire d’Etude du Polymorphisme de l’ADN, Faculte´ de Me´-
decine 1, rue Gaston Veil, 44035, Nantes Cedex, France. E-mail:
lecaignec@hotmail.com
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7101-0021$15.00
mRNA is abundantly expressed during development, and
targeted disruption of Jag1 in mice results in vascular
defects and embryonic lethality (Loomes et al. 1999; Xue
et al. 1999). The JAG1 protein has several domains that
show high interspecies conservation, including an N-
terminal “DSL” motif found in the Delta, Serrate, and
Lag-2 ligands in the Notch family; 16 tandemly repeated
epidermal-growth-factor (EGF)–like domains; and a
transmembrane region (Lindsell et al. 1995; Oda et al.
1997). Among the 16 EGF-like domains, the first and
second ones have been shown to be important for the
formation of a high-affinity complex with Notch (Shimizu
et al. 1999). Mutations in JAG1 have been identified in
∼70% of patients with Alagille syndrome (AGS [MIM
118450]), a rare autosomal dominant condition (Krantz
et al. 1998; Yuan et al. 1998; Crosnier et al. 1999, 2001;
Onouchi et al. 1999; Pilia et al. 1999; Heritage et al. 2000;
Colliton et al. 2001; Giannakudis et al. 2001; Spinner et
al. 2001) that comprises three of these five main features:
paucity of intrahepatic bile ducts, congenital heart defects
(predominantly peripheral pulmonic stenosis), skeletal de-
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Figure 1 Pedigree of the family with deafness and congenital
heart defects, showing three-locus genotypes and inferred haplo-
types. Unblackened symbols denote unaffected individuals; black-
ened symbols denote affected individuals. Genotypes are shown in
the following order, from top to bottom: D20S115, D20S186, and
D20S112. The arrow indicates the proband.
fects, ocular anomalies, and characteristic facies (Alagille
et al. 1975; Krantz et al. 1997). The absence of phenotyp-
ic differences between total gene deletions and protein-
truncating mutations suggests that haploinsufficiency is a
pathogenic mechanism causing AGS (Krantz et al. 1998;
Crosnier et al. 1999). To date, 26 unique missense mu-
tations have been identified in JAG1,most of them leading
to AGS. A missense mutation (G274D) in JAG1 has also
been identified, in a kindred with right-heart obstructive
disease and characteristic facies, that is distinct from that
seen in AGS (Eldadah et al. 2001). In addition, two mouse
mutants, Slalom and Headturner, showed that missense
mutations (P269S and G289D, respectively) in the second
EGF-like domain of the Jag1 gene lead to disturbances of
the patterning of the organ of Corti in the inner ear (Kier-
nan et al. 2001; Tsai et al. 2001).
We studied a kindred (eight affected patients and seven
unaffected individuals) with mild-to-severe combined
deafness and congenital heart defects segregating as au-
tosomal dominant traits (fig. 1). Auditory thresholds
were determined by standard pure-tone audiometry with
air and bone conductions at 250–8,000 Hz. In addition,
previous audiological tests were collected. The pheno-
type of affected patients in this family was variable (table
1). Six of seven available affected individuals manifested
mild-to-severe combined hearing loss, predominantly af-
fecting middle frequencies. Two patients were diagnosed
with vestibular pathology consistent with unstable equi-
librium most prevalent during walking. To characterize
vestibular dysfunction, a computed tomography (CT)
scan was performed on patient III-6 and revealed bilat-
eral aplasia of the anterior semicircular canal and hy-
poplasia of the posterior semicircular canal (fig. 2). All
patients, who were evaluated in the Service de Cardiol-
ogie at CHU, exhibited congenital heart disease, includ-
ing tetralogy of Fallot (ToF [MIM 187500]), ventricular
septal defect (VSD), and/or peripheral pulmonic stenosis
(PPS). Patient II-7 had ToF that did not allow surgical
correction, because of severe PPS. He also had severe
combined hearing loss that required a hearing aid (fig.
3), as well as vestibular dysfunction. One of his daugh-
ters (III-8) had very severe ToF, defined as the presence
of pulmonary atresia and ventricular septal defect, which
had been successfully surgically corrected in early child-
hood. Her audiogram was normal. His second daughter
(III-6) had a VSD that spontaneously closed, as well as
moderate combined hearing loss that required surgical
correction and a hearing aid, associated with vestibular
dysfunction. Patient II-1 had VSD, PPS, and moderate
combined hearing loss. Patients II-2, II-3, and III-1 had
isolated PPS and mild-to-moderate combined hearing
loss. Patient III-2 had acute lymphoblastic leukemia and
died at age 2.5 years; autopsy showed isolated PPS. All
individuals had normal growth and cognition. No his-
tory of hepatic dysfunction was noted for any of the
patients.
Our protocol was approved by the appropriate insti-
tutional review boards. After informed consent was ob-
tained, blood samples were collected from 14 family mem-
bers. FISH analysis excluded microdeletion at 22q11, a
common cause of syndromic and isolated conotruncal
heart defects. Genomic DNA was prepared from periph-
eral lymphocytes. Linkage analysis was performed by
standard methods, through use of fluorescence-labeled
polymorphic STRs (ABI Prism Linkage Mapping Set ver-
sion 2). Genotypes were analyzed with an ABI 377 au-
tomated sequencer. Alleles were assigned using the Ge-
notyper version 2.0 program. Two-point linkage analysis
was calculated using the MLINK program version 5.1,
assuming a disease penetrance of 0.95. Because congenital
heart defects are linked to mutations in JAG1 orNKX2.5
in humans and in TBX1 or NTF3 in mice, we considered
these genes as suitable candidates (Donovan et al. 1996;
Schott et al. 1998; Eldadah et al. 2001; Jerome and Pa-
paioannou 2001; Lindsay et al. 2001; Merscher et al.
2001). Linkage analysis excluded the NKX2.5, TBX1,
and NTF3 loci but was conclusive for marker D20S186,
in the vicinity of the JAG1 gene (maximum LOD score
[Zmax] 3.01 at recombination fraction 0.00) (Lathrop and
Lalouel 1984). Mutation analysis was conducted by direct
sequencing of the JAG1 gene through use of an ABI 377
automated sequencer. All exons were amplified using pre-
viously described primers (Krantz et al. 1998). Direct se-
quencing of JAG1 was performed on an affected family
member (II-7). An amplicon spanning JAG1 exon 5 re-
vealed heterozygosity for a GrA transition at nucleotide
701 of the coding sequence, predicting substitution of
cysteine (C) for tyrosine (Y) at position 234 (C234Y) of
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Table 1
Comparison of the Clinical Features of Affected Individuals in the Family, with the Frequencies of Clinical Criteria in Patients with AGS
PATIENT
OR SAMPLE
CLINICAL FEATUREa
Cardiac
Disease Deafness
Vestibular
Pathology
Chronic
Cholestasis
Ocular
Abnormalities
Caracteristic
Facies
Vertebral
Anomalies
Growth
Retardation
Renal
Dysfunction
Mental
Retardation
II-7 ToF Severe        
III-6 VSD Moderate        
III-8 ToF         
II-1 VSD, PPS Moderate        
II-2 PPS Mild        
II-3 PPS Mild        
III-1 PPS Mild        
III-2 PPS NA NA NA NA  NA   NA
Patients with AGSb 92% Rare Rare 95% 78% 91% 70% 50%–90% 23%–74% 0%–16%
a  p Present;  p absent; NA p not available.
b Data are from Krantz et al. (1997) and are expressed as percentages of patients showing each clinical feature.
Figure 2 A, Axial CT scan of patient III-6, showing aplasia of the
anterior semicircular canal (a) and hypoplasia of the posterior semicir-
cular canal (p). B, Comparison with an unaffected individual.
the JAG1 protein (fig. 4). The mutation occurred within
the first of the 16 tandemly repeated EGF-like domains
of JAG1. This sequence change was confirmed in all af-
fected individuals with available genomic DNA ( )np 7
in this family but was absent in unaffected family mem-
bers. No DNA was available for the deceased sibling with
PPS (III-2). C234Y was not found in 120 chromosomes
from unrelated and unaffected individuals. Since the
JAG1 gene has been shown to cause AGS, a clinical ge-
neticist (C.L.C.) reexamined all affected patients for sub-
clinical manifestations of this syndrome. In all gene car-
riers, no characteristic facies or vertebral defects were
identified, but all had asymptomatic posterior embry-
otoxon. Blood examination showed normal electrolytes,
calcium, urea nitrogen, creatinine, total and direct bili-
rubin, transaminases, gamma-glutamyl transferase, and
alkaline phosphatase consistent with normal renal and
hepatic functions.
Deafness has been described in a few patients with
AGS and cytogenetically visible deletions on 20p (Anad
et al. 1990) but in none of the studies of large samples
of patients with AGS. Therefore, hearing loss has been
reported in patients with AGS who have chromosom-
al abnormalities on 20p (Krantz et al. 1997), suggesting
a contiguous gene syndrome. First, however, the JAG1
gene is expressed in the sensory regions of the ear (Cros-
nier et al. 2000). Second, the mouse mutant Headturner
showed dominant head-shaking behavior indicative of
a vestibular defect. It also demonstrates disturbances of
the patterning of the organ of Corti in the inner ear,
characterized by reduced numbers of outer hair cells, as
well as loss of sensory structures in the vestibular sys-
tem, including missing posterior and sometimes anterior
ampulae and a truncation of the respective semicircular
canals (Kiernan et al. 2001). Despite these patterning
anomalies in the organ of Corti, Headturner mutants
were not deaf but had slightly raised thresholds for com-
pound action potentials, which is an indication of co-
chlear nerve responses, although these differences were
not significant. A similar phenotype has also been seen
in the mouse mutant Slalom, which also carries a mu-
tation in Jag1 (Tsai et al. 2001). Third, severe anomalies
have been observed in temporal bones of four individ-
uals with AGS. These patients exhibited partially or to-
tally absent posterior and anterior semicircular canals.
The cochlea was observed to be shortened in one case.
An audiogram of one patient showed a bilateral mod-
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Figure 3 Representative audiogram for the family (individual II-7)
Figure 4 Sequence chromatograms showing the mutation found
in the kindred. A, Sequencing data from individual II-8, representing the
normal JAG1 allele. B, Sequencing data from an affected patient (II-7),
representing the normal and the mutant JAG1 alleles. A GrA transition
changes the codon for cysteine (TGC) in position 234 of the JAG1protein
to the codon for tyrosine (TAC).
erate combined hearing loss (Okuno et al. 1990). Finally,
hearing loss was described in a large kindred with clas-
sical AGS (LaBrecque et al. 1982). Patients were found
to have normal karyotypes. The father and two children
demonstrated a mild conductive hearing loss. At least
two other family members were known to have hearing
difficulties. The present study describes six of seven
C234Y carriers with mild-to-severe combined hearing
loss. JAG1 C234Y is the first mutation described in a
large kindred with hearing loss.
The vast majority of JAG1 mutations that cause AGS
create premature termination codons, which predict an
unstable message or the expression of truncated poly-
peptides that lack essential domains (Krantz et al. 1998;
Crosnier et al. 1999). AGS is also caused by hemizy-
gosity for JAG1, establishing haploinsufficiency as the
relevant pathogenetic mechanism. However, the mech-
anism by which missense mutations in AGS lead to dis-
ease is unknown, and a dominant negative mechanism
cannot be ruled out. In Drosophila, mutant Delta and
Serrate (Notch ligands that are highly homologous to
JAG1) act in a dominant negative fashion (fig. 5A) (Re-
bay et al. 1991; Sun and Artavanis-Tsakonas 1996).
Among the 26 unique missense mutations identified in
JAG1, 12 occurred in the EGF repeats (fig. 5A). Eight
result in loss or gain of a conserved cysteine residue that
forms intramolecular disulfide linkages, an event known
to perturb folding and to target proteolytic degradation
in other proteins (Schrijver et al. 1999). Each EGF-like
domain contains six cysteine residues that form stable
disulfide bridges creating stable three-dimensional con-
formations. Cysteine substitutions disrupt one of three
disulfide bridges that covalently connect three pairs of
cysteine residues that are highly conserved in EGF-like
domains (Aoyama et al. 1993; Downing et al. 1996).
This has a predictable detrimental effect on the domain
itself, as shown in structural studies of similar domains
in other proteins, but it also interferes with calcium bind-
ing even when the required consensus sequence is intact
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Figure 5 A, Schematic diagram of human JAG1, mouse Jag1, and
Drosophila Delta and Serrate protein structures, and the locations of
missense mutations identified in EGF-like domains of human JAG1 and
in the second EGF-like domain of mouse Jag1. The arrows indicate C-
terminal deletions of Delta and Serrate. Superscripts associated with
mutations are as follows: apmissense mutation described in the present
study; b p mutation described in a kindred segregating ToF and char-
acteristic facies; c p mutations described in patients with AGS; d p
mutation described in mouse Slalom mutant; e p mutation described
in mouse Headturner mutant. SP p signal peptide; DSL p conserved
domain shared by Delta, Serrate, and Lag2; CRp cysteine-rich region;
TM p transmembrane domain; IC p intracellular domain. B, Align-
ment of the amino acid sequence of the first EGF-like domain of human
JAG1 with the corresponding sequences of the first EGF-like domain of
human JAG2, the second EGF-like domain of human JAG1, and those
from other species. Note the first cysteine is conserved in all of the wild-
type sequences.
(Reinhardt et al. 1997). The novel missense mutation
we describe implicates the first cysteine in the first EGF-
like domain that disrupts the C1-C3 disulfide bridge and
probably affects calcium binding. The mutation alters a
residue that is conserved through evolution within this
and the other EGF-like domains of JAG1, as well as
other proteins, including Jagged 2, Delta, and Serrate
(fig. 5B ).
In the present study, we describe a kindred segregating
a unique phenotype with highly penetrant deafness, pos-
terior embryotoxon, and congenital heart defects. We
have identified a novel missense mutation (C234Y) in
the extracellular domain of JAG1 in the first of the 16
EGF-like domains, which demonstrates that mutations
in JAG1 can cause hearing loss. In the presence of a
congenital heart defect suggestive of AGS-associated car-
diopathies, a audiological test in infancy should be pro-
posed. Further studies of the missense mutations in the
EGF-like repeats of JAG1 may provide new insights in
JAG1-related diseases.
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